GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Technologies Ltd (STU:DU8) » Definitions » Shiller PE Ratio

Genetic Technologies (STU:DU8) Shiller PE Ratio : (As of May. 24, 2024)


View and export this data going back to . Start your Free Trial

What is Genetic Technologies Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Genetic Technologies Shiller PE Ratio Historical Data

The historical data trend for Genetic Technologies's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetic Technologies Shiller PE Ratio Chart

Genetic Technologies Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Genetic Technologies Quarterly Data
Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Genetic Technologies's Shiller PE Ratio

For the Diagnostics & Research subindustry, Genetic Technologies's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genetic Technologies's Shiller PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Technologies's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Genetic Technologies's Shiller PE Ratio falls into.



Genetic Technologies Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Genetic Technologies's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Genetic Technologies's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0/126.3989*126.3989
=0.000

Current CPI (Dec. 2023) = 126.3989.

Genetic Technologies Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
200812 -0.418 85.814 -0.616
200906 -0.642 86.278 -0.941
200912 -0.635 87.578 -0.916
201006 -0.887 88.971 -1.260
201012 0.771 89.993 1.083
201106 -0.605 92.129 -0.830
201112 -0.574 92.686 -0.783
201203 0.000 92.779 0.000
201206 -0.260 93.244 -0.352
201212 -0.595 94.730 -0.794
201303 0.000 95.101 0.000
201306 -0.782 95.473 -1.035
201312 -0.618 97.330 -0.803
201406 -0.482 98.352 -0.619
201412 -0.425 99.002 -0.543
201506 -0.149 99.838 -0.189
201512 -0.155 100.673 -0.195
201606 -0.148 100.859 -0.185
201612 -0.143 102.159 -0.177
201706 -0.113 102.809 -0.139
201712 -0.084 104.110 -0.102
201806 -0.057 104.945 -0.069
201812 -0.076 105.967 -0.091
201906 -14.676 106.617 -17.399
201912 -0.050 107.917 -0.059
202006 -0.043 106.246 -0.051
202009 0.000 107.917 0.000
202012 -0.031 108.846 -0.036
202103 0.000 109.496 0.000
202106 -0.019 110.332 -0.022
202109 0.000 111.168 0.000
202112 -0.025 112.654 -0.028
202203 0.000 115.069 0.000
202206 -0.027 117.112 -0.029
202209 0.000 119.248 0.000
202212 -0.038 121.477 -0.040
202303 0.000 123.148 0.000
202306 0.030 124.170 0.031
202309 0.000 125.656 0.000
202312 0.000 126.399 0.000

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Genetic Technologies  (STU:DU8) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Genetic Technologies Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Genetic Technologies's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Genetic Technologies (STU:DU8) Business Description

Traded in Other Exchanges
Address
60-66 Hanover Street, Fitzroy, Melbourne, VIC, AUS, 3065
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.

Genetic Technologies (STU:DU8) Headlines

No Headlines